Table 3.

Factors associated with the rise of Child-Pugh scores after transcatheter arterial chemoembolization and radiofrequency ablation combination

Factors		n	Rise of CPs at 1mo events		P	Rise of CPs at 12 mo events		P
Gender	Male	69	4	(5.8%)	1.000	2	(2.9%)	0.287
	Female	25	1	(4.0%)		2	(8.0%)
Age (yr)	≥ 60	46	1	(2.2%)	0.362	2	(4.3%)	1.000
	< 60	48	4	(8.3%)		2	(4.2%)
Etiology of HCC	HBV	72	4	(5.6%)	1.000	2	(2.8%)	0.232
	Others	22	1	(4.5%)		2	(9.1%)
CP class	A	67	2	(3.0%)	0.141	2	(3.0%)	0.576
	B	27	3	(11.1%)		2	(7.4%)
CP score	score 5-7	80	2	(2.5%)	0.022	3	(3.8%)	0.481
	score 8-9	14	3	(21.4%)		1	(7.1%)
Diameter of HCC (cm)	> 3.0	22	3	(13.6%)	0.082	1	(4.5%)	0.856
	≤ 3.0	72	2	(2.8%)		3	(4.2%)
Multiplicity of HCC	≥ 2.0	24	3	(12.5%)	0.103	1	(4.2%)	1.000
	single	70	2	(2.9%)		3	(4.3%)
AFP (ng/mL)	> 100	19	1	(5.3%)	1.000	0	(0.0%)	0.579
	≤ 100	75	4	(5.3%)		4	(5.3%)
TACE-RFA interval (d)	same day	27	3	(11.1%)	0.141	2	(7.4%)	0.576
	1-2	67	2	(3.0%)		2	(3.0%)
Major complications	Yes	3	0	(0.0%)	1.000	1	(33.3%)	0.124
	No	91	5	(5.5%)		3	(3.3%)
Rise of CPs at 1 mo	Yes	5				1	(20.0%)	0.199
	No	89				3	(3.4%)

P value was calculated by Fisher’s exact test. AFP: α-Fetoprotein; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; RFA: Radiofrequency ablation; TACE: Transcatheter arterial chemoembolization.